ACELRX PHARMACEUTICALS INC's ticker is ACRX and the CUSIP is 00444T100. A total of 73 filers reported holding ACELRX PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $11,000 | +57.1% | 46,493 | +90.3% | 0.00% | – |
| Q1 2022 | $7,000 | -63.2% | 24,437 | -29.2% | 0.00% | – |
| Q4 2021 | $19,000 | -38.7% | 34,502 | +14.1% | 0.00% | – |
| Q3 2021 | $31,000 | -59.7% | 30,226 | -45.8% | 0.00% | – |
| Q2 2021 | $77,000 | +381.2% | 55,763 | +320.1% | 0.00% | – |
| Q4 2020 | $16,000 | 0.0% | 13,275 | +15.0% | 0.00% | – |
| Q3 2020 | $16,000 | -30.4% | 11,540 | -39.1% | 0.00% | – |
| Q2 2020 | $23,000 | -90.7% | 18,961 | -80.5% | 0.00% | – |
| Q2 2019 | $246,000 | +170.3% | 97,127 | +272.7% | 0.00% | – |
| Q1 2019 | $91,000 | +116.7% | 26,063 | +108.8% | 0.00% | – |
| Q2 2018 | $42,000 | -22.2% | 12,481 | +7.2% | 0.00% | – |
| Q3 2017 | $54,000 | -82.2% | 11,642 | -83.7% | 0.00% | -100.0% |
| Q2 2015 | $303,000 | -42.0% | 71,556 | -24.7% | 0.00% | -60.0% |
| Q3 2014 | $522,000 | +83.2% | 95,006 | +299.8% | 0.01% | +66.7% |
| Q1 2014 | $285,000 | – | 23,762 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 6,574,060 | $25,376,000 | 1.97% |
| SENZAR ASSET MANAGEMENT, LLC | 1,040,681 | $4,017,000 | 0.98% |
| Cormorant Asset Management, LP | 850,000 | $3,281,000 | 0.51% |
| Palo Alto Investors LP | 2,135,739 | $8,244,000 | 0.41% |
| Opus Point Partners Management, LLC | 99,959 | $386,000 | 0.32% |
| Granahan Investment Management | 1,527,837 | $5,897,000 | 0.17% |
| WALL STREET ASSOCIATES | 367,200 | $1,417,000 | 0.13% |
| CAXTON CORP | 21,870 | $84,000 | 0.10% |
| SHEPHERD KAPLAN KROCHUK, LLC | 107,392 | $415,000 | 0.07% |
| Joel Isaacson & Co., LLC | 70,660 | $273,000 | 0.07% |